LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Book: Data needs in oncology: "Making sense of the big data soup"

    DeMartino, Jessica / Larsen, Jonathan K.

    (Journal of the National Comprehensive Cancer Network ; 11, Suppl. 2)

    2013  

    Author's details Jessica K. DeMartino and Jonathan K. Larsen
    Series title Journal of the National Comprehensive Cancer Network ; 11, Suppl. 2
    Collection
    Language English
    Size [15] S. : Kt.
    Publisher Harborside Press
    Publishing place Cold Spring Harbor, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT018701232
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6365 -11,Suppl.2- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Equity in cancer care: pathways, protocols, and guidelines.

    DeMartino, Jessica K / Larsen, Jonathan K

    Journal of the National Comprehensive Cancer Network : JNCCN

    2012  Volume 10 Suppl 1, Page(s) S1–9

    Abstract: The quality of patient care varies based on numerous factors, such as health care setting, geographic location, access to medications, insurance coverage, and treatment protocols. Recently, the issue of whether use of clinical pathways can reduce costs ... ...

    Abstract The quality of patient care varies based on numerous factors, such as health care setting, geographic location, access to medications, insurance coverage, and treatment protocols. Recently, the issue of whether use of clinical pathways can reduce costs and inappropriate variability in care has been the subject of much debate. As clinical treatment guidelines and pathways are increasingly deployed in oncology practice, they have a growing impact on the quality of treatment and how it is delivered. To fulfill the current need to discuss the use of pathways and clinical treatment guidelines in oncology and to address how patient care is impacted by their use, the National Comprehensive Cancer Network convened the NCCN Oncology Policy Summit: Equity in Cancer Care-Pathways, Protocols, and Guidelines. The summit was a forum to discuss the use and implementation of pathways, including how much flexibility pathways should allow in care, pathways' impact on public and private health insurance benefit design, what data is used to select pathway regimens and protocols, and ultimately what impact pathways may have on variation in care. The use and implementation of clinical treatment guidelines in practice was also explored from a variety of perspectives.
    MeSH term(s) Clinical Protocols/standards ; Critical Pathways/legislation & jurisprudence ; Critical Pathways/organization & administration ; Drug Industry/economics ; Drug Industry/legislation & jurisprudence ; Drug Industry/organization & administration ; Health Services Accessibility/legislation & jurisprudence ; Health Services Accessibility/organization & administration ; Humans ; Medical Oncology/legislation & jurisprudence ; Medical Oncology/methods ; Medical Oncology/organization & administration ; Medical Oncology/trends ; Neoplasms/economics ; Neoplasms/therapy ; Practice Guidelines as Topic ; Quality of Health Care/legislation & jurisprudence ; Quality of Health Care/organization & administration ; Societies, Medical/legislation & jurisprudence ; Societies, Medical/organization & administration ; Standard of Care/economics ; Standard of Care/legislation & jurisprudence ; Standard of Care/organization & administration ; Standard of Care/trends ; United States
    Language English
    Publishing date 2012-10-02
    Publishing country United States
    Document type Congress
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2012.0164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: International adaptations of NCCN Clinical Practice Guidelines in Oncology.

    Carlson, Robert W / Larsen, Jonathan K / McClure, Joan / Fitzgerald, C Lyn / Venook, Alan P / Benson, Al B / Anderson, Benjamin O

    Journal of the National Comprehensive Cancer Network : JNCCN

    2014  Volume 12, Issue 5, Page(s) 643–648

    Abstract: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are ...

    Abstract The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) are evidence- and consensus-based clinical practice guidelines addressing malignancies that affect more than 97% of all patients with cancer in the United States. The NCCN Guidelines are used extensively in the United States and globally. Use of the guidelines outside the United States has driven the need to adapt the guidelines based on local, regional, or national resources. The NCCN Guidelines Panels created, vetted, and continually update the NCCN Guidelines based on published scientific data on cancer detection, diagnosis, and treatment efficacy. The guidelines are developed within the context of commonly available resources, methods of payment, societal and cultural expectations, and governmental regulations as they exist in the United States. Although many of the cancer management recommendations contained in the NCCN Guidelines apply broadly from a global perspective, not all do. Disparities in availability and access to health care exist among countries, within countries, and among different social groups in the same country, especially regarding resources for cancer prevention, early detection, and treatment. In addition, different drug approval and payment processes result in regional variation in availability of and access to cancer treatment, especially highly expensive agents and radiation therapy. Differences in cancer risk, predictive biomarker expression, and pharmacogenetics exist across ethnic and racial groups, and therefore across geographic locations. Cultural and societal expectations and requirements may also require modification of NCCN Guidelines for use outside the United States. This article describes the adaptation process, using the recent Latin American adaptation of the 2013 NCCN Guidelines for Colorectal Cancer as an example.
    MeSH term(s) Global Health ; Humans ; Neoplasms ; Practice Guidelines as Topic ; United States
    Language English
    Publishing date 2014-04-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2014.0068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

    Zelenetz, Andrew D / Ahmed, Islah / Braud, Edward Louis / Cross, James D / Davenport-Ennis, Nancy / Dickinson, Barry D / Goldberg, Steven E / Gottlieb, Scott / Johnson, Philip E / Lyman, Gary H / Markus, Richard / Matulonis, Ursula A / Reinke, Denise / Li, Edward C / DeMartino, Jessica / Larsen, Jonathan K / Hoffman, James M

    Journal of the National Comprehensive Cancer Network : JNCCN

    2011  Volume 9 Suppl 4, Page(s) S1–22

    Abstract: Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics (biosimilars), which raises important considerations for the ...

    Abstract Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics (biosimilars), which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer. The potential for biosimilars to reduce the cost of biologics, which are often high-cost components of oncology care, was the impetus behind the Biologics Price Competition and Innovation Act of 2009, a part of the 2010 Affordable Care Act. In March 2011, NCCN assembled a work group consisting of thought leaders from NCCN Member Institutions and other organizations, to provide guidance regarding the challenges health care providers and other key stakeholders face in incorporating biosimilars in health care practice. The work group identified challenges surrounding biosimilars, including health care provider knowledge, substitution practices, pharmacovigilance, naming and product tracking, coverage and reimbursement, use in off-label settings, and data requirements for approval.
    MeSH term(s) Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/economics ; Biosimilar Pharmaceuticals/therapeutic use ; Drug Approval/legislation & jurisprudence ; Drug Approval/organization & administration ; Drugs, Generic/economics ; Drugs, Generic/therapeutic use ; Europe ; Humans ; Neoplasms/drug therapy ; United States ; World Health Organization
    Chemical Substances Antineoplastic Agents ; Biosimilar Pharmaceuticals ; Drugs, Generic
    Language English
    Publishing date 2011-09-30
    Publishing country United States
    Document type Consensus Development Conference ; Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2011.0136
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

    Engstrom, Paul F / Bloom, Mara G / Demetri, George Daniel / Febbo, Phillip G / Goeckeler, William / Ladanyi, Marc / Loy, Bryan / Murphy, Kate / Nerenberg, Michael / Papagni, Paul / Robson, Mark / Sweetman, Robert W / Tunis, Sean / Demartino, Jessica / Larsen, Jonathan K

    Journal of the National Comprehensive Cancer Network : JNCCN

    2011  Volume 9 Suppl 6, Page(s) S1–16

    Abstract: Personalized medicine in oncology is maturing and evolving rapidly, and the use of molecular biomarkers in clinical decision-making is growing. This raises important issues regarding the safe, effective, and efficient deployment of molecular tests to ... ...

    Abstract Personalized medicine in oncology is maturing and evolving rapidly, and the use of molecular biomarkers in clinical decision-making is growing. This raises important issues regarding the safe, effective, and efficient deployment of molecular tests to guide appropriate care, specifically regarding laboratory-developed tests and companion diagnostics. In May 2011, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify challenges and provide guidance regarding molecular testing in oncology and its corresponding utility from clinical, scientific, and coverage policy standpoints. The NCCN Molecular Testing Work Group identified challenges surrounding molecular testing, including health care provider knowledge, determining clinical utility, coding and billing for molecular tests, maintaining clinical and analytic validity of molecular tests, efficient use of specimens, and building clinical evidence.
    MeSH term(s) Biomarkers, Tumor/analysis ; Humans ; Medical Oncology/methods ; Medical Oncology/standards ; Medical Oncology/trends ; Molecular Biology/methods ; Molecular Biology/standards ; Molecular Biology/trends ; Neoplasms/diagnosis ; Neoplasms/genetics
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2011-12-22
    Publishing country United States
    Document type Guideline ; Journal Article
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2011.0138
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top